



## Nam Quoc Bui

Clinical Associate Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Sarcoma Program**

900 Blake Wilbur Dr 2nd Floor

MC 6511

Stanford, CA 94305

Tel (650) 498-6000      Fax (650) 725-2441

### Bio

---

#### BIO

Dr. Bui is a Clinical Associate Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.

He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to medical students, residents, and oncology fellows. Dr. Bui is the founding Editor-in-Chief of the journal "Current Problems in Cancer: Case Reports", an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer. He also serves as the Chair of the Data Safety Monitoring Committee at the Stanford Cancer Institute, overseeing the board that reviews all investigator-initiated cancer trials run at Stanford.

#### CLINICAL FOCUS

- Medical Oncology
- Soft Tissue Sarcoma
- Bone Sarcoma
- Gastrointestinal Stromal Tumors (GIST)

#### ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

## ADMINISTRATIVE APPOINTMENTS

- Chair, Data and Safety Monitoring Committee, Stanford Cancer Institute, (2025- present)
- Member, Data and Safety Monitoring Committee, Stanford Cancer Institute, (2020- present)

## BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Clinical Oncology (ASCO) (2014 - present)
- Associate Member, Stanford Cancer Institute (2018 - present)
- Member, Connective Tissue Oncology Society (CTOS) (2017 - present)

## PROFESSIONAL EDUCATION

- Residency: Stanford University Internal Medicine Residency (2014) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2017)
- Fellowship: UCSD Hematology and Oncology Training (2017) CA
- Board Certification: Hematology, American Board of Internal Medicine (2017)
- Medical Education: University of Texas Southwestern Medical School Registrar (2011) TX
- Board Certification: Internal Medicine, American Board of Internal Medicine (2014)
- B.S., Stanford University , Computer Science (2007)

## LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>
- Current Problems in Cancer: Case Reports: <https://www.sciencedirect.com/journal/current-problems-in-cancer-case-reports>

## Research & Scholarship

---

### CLINICAL TRIALS

- A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors, Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- FOG-001 in Locally Advanced or Metastatic Solid Tumors, Recruiting
- Phase 1 Study of Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal , Recruiting
- Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor, Recruiting
- Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo), Recruiting
- Phase I ADCT-502 in Advanced Solid Tumors with HER2 Expression, Not Recruiting
- Phase I TRK Inhibitor Selitrectinib-BAY 2731954 in Adult & Pediatric PreviouslyTx NTRK FusionCancers, Not Recruiting
- Phase I/II Urelumab in Combo w/ Nivolumab in Advanced/Metastatic Solid Tumors & B Cell NHL, Not Recruiting
- Phase I/IIa Open-Label Study of SQ3370 in Advanced Solid Tumors, Not Recruiting
- Phase II ADI-PEG 20 in Combo w/ Gemcitabine & Docetaxel in Tx of Sarcomas & Small Cell Lung Cancer, Not Recruiting
- Phase II Olaparib in Combo w/ DNA Damaging Agent Temozolomide in Advanced Uterine Leiomyosarcoma, Not Recruiting
- Phase II PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors, Not Recruiting
- Phase III AL3818(Catequentinib-Anlotinib) MonoTx in Mets/AdvncdSarcoma /Leiomyosarcoma /SynovialSarc, Not Recruiting
- Phase III Nirogacestat vs Placebo in Adult Progressing Desmoid Tumors/Aggressive Fibromatosis(DT/AF), Not Recruiting
- Phase III Study of Milademetan vs Trabectedin in Patients with Dedifferentiated Liposarcoma, Not Recruiting

- RINGSIDE: Phase II/III AL102 in Progressing Desmoid Tumors, Not Recruiting
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma, Not Specified
- SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma, Not Specified

## Publications

---

### PUBLICATIONS

- **A Multi-center Retrospective Outcomes Analysis of Patients with Localized Synovial Sarcoma.** *Cancer research communications*  
Testa, S., Zhou, M. Y., Schulte, B. C., Wang, V. E., Kenny, K., Peng, A., Lohman, M., Desai, A. M., Bockorny, B., Baghian, A., Schmidt, D. R., Bui, N. Q., Pan, et al  
2026
- **Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Ratan, R., Kasper, B., Alcindor, T., Schöffski, P., van der Graaf, W. T., Federman, N., Bui, N. Q., D'Amato, G., Riedel, R. F., Attia, S., Chawla, S., Lim, A., Tumminello, et al  
2026: JCO2600107
- **p53 drives lung cancer regression through a TSC2/TFEB-dependent senescence program.** *Cancer discovery*  
Wang, M., Biegging-Rolett, K. T., Kaiser, A. M., Brady, C. A., Lockhart, J. H., Ferreira, S., Nguyen, K. T., Rajeevan, A., Evans, S. A., Zhao, T., Raj, N., Elkrief, A., Tischfield, et al  
2025
- **Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Ratan, R., Kasper, B., Alcindor, T., Schöffski, P., van der Graaf, W. T., Federman, N., Bui, N. Q., D'Amato, G., Riedel, R. F., Attia, S., Chawla, S., Lim, A., Tumminello, et al  
2025: JCO2500582
- **Pseudomyogenic Hemangioendothelioma Treated with Zoledronic Acid: A Case Report.** *JBJS case connector*  
McGovern, A. G., Bui, N. Q., Charville, G. W., Guja, K. E., Steffner, R. J.  
2025; 15 (4)
- **Pseudomyogenic Hemangioendothelioma Treated with Zoledronic Acid: A Case Report.** *JBJS case connector*  
McGovern, A. G., Bui, N. Q., Charville, G. W., Guja, K. E., Steffner, R. J.  
2025; 15 (4)
- **SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.** *Genome medicine*  
Testa, S., Pal, A., Subramanian, A., Varma, S., Tang, J. P., Graham, D., Arfan, S., Pan, M., Bui, N. Q., Ganjoo, K. N., Dry, S., Huang, P., van de Rijn, et al  
2025; 17 (1): 89
- **Development and implementation of cancer clinical trial patient screening using an electronic medical record-integrated trial matching system.** *BMJ health & care informatics*  
Bui, N., Nika, A., Montoya, M., Lopez, A., Newman, J., Vaddadi, M., Guli, R., Rodin, M., Robinson, A., Rosenthal, E., Artandi, S. E., Ather, S., Pang, et al  
2025; 32 (1)
- **From the immunotherapy case files** *CURRENT PROBLEMS IN CANCER: CASE REPORTS*  
Zhang, E., Bui, N. Q.  
2025; 18
- **A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).**  
Jones, R., Chawla, N., Attia, S., Pollack, S., Cranmer, L. D., Lopez-Pousa, A., Seetharam, M., Burgess, M., Chmielowski, B., Siontis, B. L., Trent, J. C., Wilky, B. A., Bui, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumors.**

- Chugh, R., Gounder, M. M., Singh, A. S., Van Tine, B., Andelkovic, V., Yoon, J., Choy, E., Lewin, J., Martin Broto, J., Ratan, R., Bui, N., Van Der Graaf, W. T. A., Davis, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: 11516
- **Change in T2-weighted signal intensity, change in tumor volume, and exposure-response analysis in the RINGSIDE phase 2 study of varegestat in patients with desmoid tumors.**  
Gounder, M. M., Kasper, B., Chugh, R., Singh, A. S., Van Tine, B., Andelkovic, V., Yoon, J., Choy, E., Lewin, J., Martin Broto, J., Ratan, R., Bui, N., Van Der Graaf, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025
  - **Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma.**  
Zhou, M., Pan, M., Bui, N., Ganjoo, K. N.  
LIPPINCOTT WILLIAMS & WILKINS.2025: 11531
  - **A multi-center retrospective outcomes analysis of patients with localized synovial sarcoma.**  
Testa, S., Zhou, M., Schulte, B., Wang, V., Kenny, K., Peng, A., Desai, A. M., Bockorny, B., Baghian, A., Schmidt, D. R., Okimoto, R., Bui, N., Pan, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: e23555
  - **Musculoskeletal Tumor Care Disparities Prior to Initiation of Treatment Among Newly Diagnosed Adult Patients.** *Cancers*  
Li, L. J., Bui, N., Moding, E. J., Steffner, R., Mohler, D., Ganjoo, K., Pan, M.  
2025; 17 (9)
  - **Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/ Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center.** *Diseases (Basel, Switzerland)*  
Kim, T., Hao, C., Pan, M., Ganjoo, K. N., Bui, N. Q.  
2025; 13 (3)
  - **Nirogacestat-the pathway to approval of the first treatment for desmoid tumors, a rare disease.** *Therapeutic advances in rare disease*  
Kummar, S., Bui, N., Messersmith, W. A., Whiting, J., Portnoy, M., Lim, A., Mary, L.  
2025; 6: 26330040251317546
  - **Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Lee, A. Q., Hao, C., Pan, M., Ganjoo, K. N., Bui, N. Q.  
2024
  - **Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers.** *Journal of hematology & oncology*  
Pan, M., Zhou, M., Xie, L., Bui, N., Ganjoo, K.  
2024; 17 (1): 124
  - **Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study.** *Cancers*  
Zhang, E., Farag, S., Dietz, H., Wang, D., Hirbe, A., Ganjoo, K., Van Tine, B., Zaid, S., Miah, A., Keedy, V., Davis, E., Bui, N.  
2024; 16 (22)
  - **Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy**  
Lee, A., Hao, C., Pan, M., Ganjoo, K. N., Bui, N.  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis**  
Bui, N., Kwatra, V., Ryan, C. W., Gordon, E., Aleckovic, M., Srinivasan, S., Nguyen, T., Oneto, J., Abella-Dominicis, E., Chawla, S. P.  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study**  
Vincenzi, B., Bui, N., Dileo, P., Federman, N., Riedel, R. F., Van Tine, B., Amoruccio, V., Lim, A., Oton, A. B., Kasper, B.  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study**

- Alshibany, A., Zhou, M., Warren, E., Ganjoo, K. N., Demicco, E., Feeney, J., Lee, J., Shultz, D., Spickard, E., Bui, N., Cardona, K., Salawu, A., Razak, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Prognostic factors for patients with sarcoma with brain metastases**  
Zhang, E., Farag, S., Dietz, H., Wang, D., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Miah, A. B., Zaidi, S. H., Keedy, V., Davis, E. J., Bui, N.  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy.** *Nature cancer*  
Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradic, M., Torres, I. A., Oladipo, E., New, C., Kenney, et al  
2024
  - **PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma.** *BJC reports*  
Pan, M., Zhou, M. Y., Jiang, C., Zhang, Z., Bui, N., Bien, J., Siy, A., Achacoso, N., Solorzano, A. V., Tse, P., Chung, E., Hu, W., Thomas, et al  
2024; 2 (1): 9
  - **Sex-Dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Pan, M., Zhou, M. Y., Jiang, C., Zhang, Z., Bui, N. Q., Bien, J., Siy, A., Achacoso, N., Solorzano, A. V., Tse, P., Chung, E., Thomas, S., Habel, et al  
2023
  - **Management Strategies and Outcomes in Primary Liver Angiosarcoma.** *American journal of clinical oncology*  
Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., Ganjoo, K.  
2023
  - **Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Ingham, M., Allred, J. B., Chen, L., Das, B., Kochupurakkal, B., Gano, K., George, S., Attia, S., Burgess, M. A., Seetharam, M., Boikos, S. A., Bui, N., Chen, et al  
2023: JCO2300402
  - **Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.** *Cancer research communications*  
Testa, S., Bui, N. Q., Ganjoo, K. N.  
2023; 3 (7): 1212-1223
  - **Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma**  
Van Tine, B., Eulo, V., Toeniskoetter, J., Ruff, T., Luo, J., Kemp, L., Tellez, C., Weiss, M. C., Hirbe, A. C., Meyer, C., Elias, A. D., Diamond, M., Hartner, et al  
LIPPINCOTT WILLIAMS & WILKINS.2023
  - **LBA11504 Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.** *JOURNAL OF CLINICAL ONCOLOGY*  
Eulo, V., Toeniskoetter, J., Ruff, T., Luo, J., Kemp, L., Moreno Tellez, C., Weiss, M. C., Hirbe, A. C., Meyer, C., Elias, A. D., Diamond, M., Hartner, L. P., Bui, et al  
2023; 41 (17\_SUPPL): LBA11504
  - **Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study**  
Van der Graaf, W. T. A., Gounder, M. M., Ratan, R., Ivanescu, C., Marcus, J., Bell, T., Lim, A., Smith, L., Oton, A., Alcindor, T., Schoffski, P., Wilky, B. A., Riedel, et al  
LIPPINCOTT WILLIAMS & WILKINS.2023
  - **Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.** *International journal of molecular sciences*  
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., Pan, M.  
2023; 24 (11)
  - **A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma.** *Cancers*  
Bui, N., Dietz, H., Farag, S., Hirbe, A. C., Wagner, M. J., Van Tine, B. A., Ganjoo, K., Jones, R. L., Keedy, V. L., Davis, E. J.

2023; 15 (9)

- **Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, H. C., Wang, D. S., Hwang, G. L., Ganjoo, K. N., Moding, et al  
2023
- **Nirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors.** *The New England journal of medicine*  
Gounder, M., Ratan, R., Alcindor, T., Schoffski, P., van der Graaf, W. T., Wilky, B. A., Riedel, R. F., Lim, A., Smith, L. M., Moody, S., Attia, S., Chawla, S., D'Amato, et al  
2023; 388 (10): 898-912
- **The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies.** *Cancers*  
Kim, T., Bui, N. Q.  
2023; 15 (6)
- **Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma.** *Cancers*  
Zhou, M., Bui, N., Rathore, R., Sudhaman, S., George, G. V., Malashevich, A. K., Malhotra, M., Liu, M. C., Aleshin, A., Ganjoo, K. N.  
2022; 15 (1)
- **Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy.** *Practical radiation oncology*  
Baniel, C., Yoo, C. H., Jiang, A., von Eyben, R., Mohler, D. G., Ganjoo, K., Bui, N., Donaldson, S. S., Million, L., Rijn, M. v., Moon Oh, J., Hiniker, S. M.  
2022
- **The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.** *Genes*  
Liu, L., Dehner, C., Grandhi, N., Lyu, Y., Borcharding, D. C., Chrisinger, J. S., Zhang, X., Luo, J., Tao, Y., Parkes, A., Bui, N. Q., Davis, E. J., Milhem, et al  
2022; 13 (11)
- **Interactions in CSF1-driven Tenosynovial Giant Cell Tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
van IJzendoorn, D. G., Matusiak, M., Charville, G. W., Spierenburg, G., Varma, S., Colburg, D. R., van de Sande, M. A., van Langevelde, K., Mohler, D. G., Ganjoo, K. N., Bui, N. Q., Avedian, R. S., Bovee, et al  
2022
- **Management of Patients with Newly Diagnosed Desmoid Tumors in a First-Line Setting.** *Cancers*  
Testa, S., Bui, N. Q., Charville, G. W., Avedian, R. S., Steffner, R., Ghanouni, P., Mohler, D. G., Ganjoo, K. N.  
2022; 14 (16)
- **Cutaneous Angiosarcoma of the Head and Neck-A Retrospective Analysis of 47 Patients.** *Cancers*  
Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., Ganjoo, K.  
2022; 14 (15)
- **The interaction of SWI/SNF with the ribosome regulates translation and confers sensitivity to translation pathway inhibitors in cancers with complex perturbations.** *Cancer research*  
Ulicna, L., Kimmey, S. C., Weber, C. M., Allard, G. M., Wang, A., Bui, N. Q., Bendall, S. C., Crabtree, G. R., Bean, G. R., Van Rechem, C.  
2022
- **SQ3370 in advanced solid tumors: Interim phase 1 results.**  
Chawla, S. P., Batty, K., Bhadri, V., Bui, N., Guminski, A. D., Oneto, J., Srinivasan, S., Strauss, J. F., Subbiah, V., Weiss, M. C., Wilson, R., Yee, N. A., Zacharian, et al  
AMER ASSOC CANCER RESEARCH.2022
- **Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.**  
Bose, S., Ingham, M., Chen, L., Kochupurakkal, B., Marino-Enriquez, A., Allred, J. B., George, S., Attia, S., Burgess, M., Seetharam, M., Boikos, S., Bui, N., Chen, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022

- **Interim phase 1 results for SQ3370 in advanced solid tumors.**  
Chawla, S. P., Batty, K., Aleckovic, M., Bhadri, V., Bui, N., Guminski, A., Oneto, J., Srinivasan, S., Strauss, J., Subbiah, V., Weiss, M. C., Wilson, R., Yee, et al  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Current management and recent progress in desmoid tumors.** *Cancer treatment and research communications*  
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ghanouni, P., Ganjoo, K. N.  
2022; 31: 100562
- **WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma.** *JCI insight*  
Ponce, R. K., Thomas, N. J., Bui, N. Q., Kondo, T., Okimoto, R. A.  
2022; 7 (6)
- **Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.** *PLoS one*  
Przybyl, J., Spans, L., Ganjoo, K., Bui, N., Mohler, D., Norton, J., Poultsides, G., Debiec-Rychter, M., van de Rijn, M.  
2022; 17 (1): e0262272
- **Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas.** *Cancers*  
Testa, S., Bui, N. Q., Wang, D. S., Louie, J. D., Sze, D. Y., Ganjoo, K. N.  
2022; 14 (2)
- **Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.** *Case reports in oncology*  
Lanman, T., Hayden Gephart, M., Bui, N., Toland, A., Nagpal, S.  
2021; 14 (3): 1841-1846
- **PHARMACOKINETIC AND IMMUNOLOGIC DATA FROM A PHASE I STUDY OF THE CLICK CHEMISTRY-BASED THERAPY SQ3370 IN ADVANCED SOLID TUMORS AND SOFT-TISSUE SARCOMA PROVIDES PROOF-OF-CONCEPT FOR THE CAPAC PLATFORM**  
Bhadri, V., Subbiah, V., Strauss, J., Chawla, S., Bui, N., Kwatra, V., Weiss, M., Batty, K., Zakharian, M., Oneto, J., Srinivasan, S., Yee, N., Wilson, et al  
BMJ PUBLISHING GROUP.2021: A395
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**  
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Safety and Feasibility of Cryoablation during Immunotherapy in Patients with Metastatic Soft Tissue Sarcoma.** *Journal of vascular and interventional radiology : JVIR*  
Doshi, A., Zhou, M., Bui, N., Wang, D. S., Ganjoo, K., Hwang, G. L.  
2021
- **Phase 1 trial of SQ3370 in solid tumors.**  
Guminski, A., Wang, D., Bui, N., Bhadri, V., De Silva, M., Steffner, R., Yee, N. A., Srinivasan, S., Oneto, J., Saville, M., Subbiah, V.  
AMER ASSOC CANCER RESEARCH.2021
- **Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**  
Van Tine, B., Hirbe, A. C., Luo, J., Oppelt, P., Weiss, M. C., Eulo, V., Toeniskoetter, J., Haarberg, S., Abaricia, S., Ruff, T., Bomalaski, J. S., Johnston, A., Kuo, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.**  
Ingham, M., Allred, J. B., Gano, K., George, S., Attia, S., Burgess, M., Seetharam, M., Boikos, S., Bui, N., Chen, J., Close, J., Cote, G., Thaker, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma.** *NPJ genomic medicine*  
Tolwani, A., Matusiak, M., Bui, N., Forgo, E., Varma, S., Baratto, L., Iagaru, A., Lazar, A. J., van de Rijn, M., Przybyl, J.  
2021; 6 (1): 30
- **Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib.** *Case reports in oncology*

- Testa, S., Million, L., Longacre, T., Bui, N.  
2021; 14 (2): 812-819
- **Evolving role of entrectinib in treatment of NTRK-positive tumors.** *Future oncology (London, England)*  
Chawla, N., Bui, N. Q., Seetharam, M.  
2021
  - **A Case of Isolated Leptomeningeal Progression in a Patient with NTRK Fusion plus Uterine Sarcoma**  
Lanman, T., Hayden, M., Bui, N., Nagpal, S.  
LIPPINCOTT WILLIAMS & WILKINS.2021
  - **Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma.** *JAMA network open*  
Brewster, R., Purington, N., Henry, S., Wood, D., Ganjoo, K., Bui, N.  
2021; 4 (3): e210845
  - **Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression.** *Case reports in oncology*  
Zhou, M., Bui, N., Lohman, M., van de Rjin, M., Hwang, G., Ganjoo, K.  
2021; 14 (1): 459–65
  - **Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course.** *American journal of clinical oncology*  
Yurkiewicz, I. R., Zhou, M., Ganjoo, K. N., Charville, G. W., Bolleddu, S., Lohman, M., Bui, N.  
2021
  - **A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.** *Current oncology (Toronto, Ont.)*  
Testa, S., Hu, B. D., Saadeh, N. L., Pribnow, A., Spunt, S. L., Charville, G. W., Bui, N. Q., Ganjoo, K. N.  
2021; 28 (6): 5304-5317
  - **Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review.** *Surgical oncology*  
Zhou, M., Javadi, C., Charville, G. W., Bui, N. Q., Harris, E. J., Poultides, G. A., Norton, J. A., Visser, B., Lee, B., Dua, M. M., Ganjoo, K. N.  
2021; 39: 101670
  - **Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review** *IMMUNOTHERAPY*  
Zhou, M., Bui, N., Bolleddu, S., Lohman, M., Becker, H., Ganjoo, K.  
2020; 12 (18): 1303–12
  - **SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS**  
Bhadri, V., Bui, N., Guminski, A., Oneto, J., Murthy, R., Sankhala, K., Saville, M., Srinivasan, S., Steffner, R., Subbiah, V., Wang, D., Yee, N.  
BMJ PUBLISHING GROUP.2020: A253–A254
  - **NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.**  
Ingham, M., Allred, J. B., Gano, K., George, S., Attia, S., Burgess, M., Boikos, S., Bui, N., Chen, J., Close, J., Seetharam, M., Thaker, P. H., Schwartz, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
  - **Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*  
Chen, J. W., Kunder, C. A., Bui, N. n., Zehnder, J. L., Costa, H. A., Stehr, H. n.  
2020; 25: 31–42
  - **Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria**  
Chen, J. W., Kunder, C. A., Bui, N., Zehnder, J. L., Costa, H. A., Stehr, H.  
edited by Altman, R. B., Dunker, A. K., Hunter, L., Ritchie, M. D., Murray, T., Klein, T. E.  
WORLD SCIENTIFIC PUBL CO PTE LTD.2020: 31-42
  - **Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid.** *JAAD case reports*

- Tabata, M. M., Novoa, R. A., Bui, N. Q., Zaba, L. C.  
2020; 6 (5): 447–49
- **Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.** *Immunotherapy*  
Zhou, M. n., Bui, N. n., Bolleddu, S. n., Lohman, M. n., Becker, H. C., Ganjoo, K. n.  
2020
  - **Dose escalation of tinostamustine in patients with advanced solid tumors**  
Mita, A., Loeffler, M., Bui, N., Mehrling, T., Rimmel, B. J., Natale, R. B., Kummar, S.  
AMER ASSOC CANCER RESEARCH.2019
  - **Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).**  
Bui, N., Dietz, H., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Keedy, V., Davis, E. J.  
AMER SOC CLINICAL ONCOLOGY.2019
  - **A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**  
Van Tine, B., Bui, N., Prudner, B., Bomalaski, J. S., Wu, B., Chawla, S. P., Ganjoo, K. N., Oppelt, P., Hirbe, A. C.  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers** *NATURE COMMUNICATIONS*  
Ando, M., Saito, Y., Xu, G., Bui, N. Q., Medetgul-Ernar, K., Pu, M., Fisch, K., Ren, S., Sakai, A., Fukusumi, T., Liu, C., Haft, S., Pang, et al  
2019; 10
  - **Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies** *MOLECULAR CANCER THERAPEUTICS*  
Shatsky, R., Parker, B. A., Bui, N. Q., Heisten, T., Schwab, R. B., Boles, S. G., Kurzrock, R.  
2019; 18 (5): 1001–11
  - **Contemporary management of metastatic soft tissue sarcoma.** *Current problems in cancer*  
Bui, N. Q., Wang, D. S., Hiniker, S. M.  
2019
  - **Editorial.** *Current problems in cancer*  
Bui, N. n.  
2019; 43 (4): 249
  - **A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.** *Clinical sarcoma research*  
Bui, N. Q., Przybyl, J., Trabucco, S. E., Frampton, G., Hastie, T., van de Rijn, M., Ganjoo, K. N.  
2019; 9: 12
  - **Reviewing the role of healthy volunteer studies in drug development.** *Journal of translational medicine*  
Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., Figg, W. D., Kummar, S.  
2018; 16 (1): 336
  - **Disruption of NSD1 in head and neck cancer promotes favorable chemotherapeutic responses linked to hypomethylation.** *Molecular cancer therapeutics*  
Bui, N., Huang, J. K., Bojorquez-Gomez, A., Licon, K., Sanchez, K. S., Tang, S. N., Beckett, A. N., Wang, T., Zhang, W., Shen, J. P., Kreisberg, J. F., Ideker, T.  
2018
  - **A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.** *Rare tumors*  
Bui, N. n., Kamat, N. n., Ravi, V. n., Chawla, S. n., Lohman, M. n., Ganjoo, K. N.  
2018; 10: 2036361318771771
  - **Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology** *MOLECULAR CANCER THERAPEUTICS*  
Husain, H., Nykin, D., Nam Bui, N., Quan, D., Gomez, G., Woodward, B., Venkatapathy, S., Duttagupta, R., Fung, E., Lippman, S. M., Kurzrock, R.  
2017; 16 (5): 948-955

- **Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.** *JCO clinical cancer informatics*  
Bui, N., Henry, S., Wood, D., Wakelee, H. A., Neal, J. W.  
2017; 2017
- **Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer** *MOLECULAR CANCER THERAPEUTICS*  
Husain, H., Scur, M., Murtuza, A., Bui, N., Woodward, B., Kurzrock, R.  
2017; 16 (2): 265-272
- **Molecular insights into desmoid tumors.** *Oncotarget*  
Bui, N. n., Kummar, S. n.  
2017; 8 (53): 90608–9
- **Evolution of early phase clinical trials in oncology.** *Journal of molecular medicine (Berlin, Germany)*  
Bui, N. Q., Kummar, S. n.  
2017
- **Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*  
Bui, N., Woodward, B., Johnson, A., Husain, H.  
2016; 17 (5)
- **Reactivation of hepatitis B virus after withdrawal of erlotinib** *CURRENT ONCOLOGY*  
Bui, N., Wong-Sefidan, I.  
2015; 22 (6): 430-432
- **Dorsal aesthetic lines in rhinoplasty: a quantitative outcome-based assessment of the component dorsal reduction technique.** *Plastic and reconstructive surgery*  
Mojallal, A., Ouyang, D., Saint-Cyr, M., Bui, N., Brown, S. A., Rohrich, R. J.  
2011; 128 (1): 280-288